Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + nimotuzumab as chemotherapy-free neoadjuvant therapy in resectable locally advanced head and neck squamous cell carcinoma
ChiCTR2600122175Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Major Pathological Response Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
adebrelimabnimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600122175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122175.